A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-05 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
==== Princes of the Royal Secret ==== In April 1818, a member of the Grand Orient de France named Louis de Clouet, who went by the Masonic codename d'Obernay, established a Grand Consistory of the Scottish Rite in Havana, Principes del Real Secreto (English: Princes of the Royal Secret). D'Obernay authorized the Grand Consistory to establish Lodges, chapters, and councils. He also authorized it to confer the 32nd Degree. The Grand Orient of France further authorized this work under the charter of the Grand Consistory dated April 7, 1819. Exactly how many Lodges were merged to create Principes del Real Secreto is debated. However, D'Obernay and this Grand Consistory did create several lodges, including L'Humanite, and La Constante Sophie, which received its charter directly from the Grand Orient of France. The Blue Lodges of the Grand Consistory were formed under the Gran Oriente Simbolico de la Nueva Thebaida (English: Symbolic Grand Orient of New Thebes), which was also known as the Gran Oriente Simbolico de la Isla de Cuba (English: Symbolic Grand Orient of the Island of Cuba). When the Grand Consistory was established, the Grand Orient of France relinquished their authority, handing it over to the National Grand Oriente of Spain. However, because the Grand Orient of Spain was bifurcated politically, the Cubans rejected its authority, preferring to remain autochthonous, instead of finding themselves on either side of the mainland Spanish divisions.
== History == From the Classical Period to the Medieval Period, the body and the soul were believed to be intimately connected, based on several theories put forth by the philosopher Plato. Wounds on the body were believed to correlate with wounds to the soul and vice versa; wounds were seen as an outward sign of an inward illness. Thus, a man who was wounded physically in a serious way was said to be hindered not only physically but spiritually as well. If the soul was wounded, that wound may also eventually become physically manifest, revealing the true state of the soul. Wounds were also seen as writing on the "tablet" of the body. Wounds acquired in war, for example, told the story of a soldier in a form which all could see and understand, and the wounds of a martyr told the story of their faith.
== Medical uses == Fixed dose combination of flupentixol and melitracen is indicated for the treatment of anxiety, depression, asthenia, neurasthenia, masked depression, psychosomatic affections accompanied by anxiety and apathy, menopausal depressions, and dysphoria or depression in alcoholics and drug addicts. and is primarily indicated for the following medical uses:
Sources: en.wikipedia.org
== Chemistry == Sumatriptan, also known as 5-(methylsulfamoylmethyl)-N,N-dimethyltryptamine, is a tryptamine derivative and a 5-substituted derivative of the psychedelic drug dimethyltryptamine (DMT). The experimental log P of sumatriptan is 0.8 to 0.93 and its predicted log P is 0.46 to 1.17.
== Reactions == DBNPA decomposition is dominated by two reaction pathways: pH-dependent hydrolysis and light-catalyzed reactions with reducing nucleophiles. DBNPA's electrophilic bromine atoms and electron-withdrawing cyano (-CN) group play a major role in determining its reactivity. A number of variables, including temperature, pH, light exposure, and reducing agents, have a substantial impact on the rate and mechanism of DBNPA breakdown. Different organic and inorganic byproducts could therefore develop, which could have an impact on DBNPA's toxicity and biocidal effectiveness.
There are different short-term and long-term effects that can arise from mutations. Smaller ones would be a halting of the cell cycle at numerous points. This means that a codon coding for the amino acid glycine may be changed to a stop codon, causing the proteins that should have been produced to be deformed and unable to complete their intended tasks. Because the mutations can affect the DNA and thus the chromatin, it can prohibit mitosis from occurring due to the lack of a complete chromosome. Problems can also arise during the processes of transcription and replication of DNA. These all prohibit the cell from reproduction and thus lead to the death of the cell. Long-term effects can be a permanent changing of a chromosome, which can lead to a mutation. These mutations can be either beneficial or detrimental. Cancer is an example of how they can be detrimental. Other effects of point mutations, or single nucleotide polymorphisms in DNA, depend on the location of the mutation within the gene. For example, if the mutation occurs in the region of the gene responsible for coding, the amino acid sequence of the encoded protein may be altered, causing a change in the function, protein localization, stability of the protein or protein complex. Many methods have been proposed to predict the effects of missense mutations on proteins.
1.7 L (1,686 cc) 4EE1-T, I4 8-valve SOHC, turbo-diesel, 82–88 PS (60–65 kW; 81–87 hp) / 167–168 N⋅m (123–124 lb⋅ft) (1995–1998) 2.0 L (1,998 cc) RF, I4 8-valve SOHC, 71 PS (52 kW; 70 hp) / 128 N⋅m (94 lb⋅ft) (1996–1999)
Sources: en.wikipedia.org
Khloé Alexandra Kardashian (; born June 27, 1984) is an American media personality, socialite, and businesswoman. She rose to fame starring with her family in the reality television series Keeping Up with the Kardashians from 2007 to 2021. Its success led to the creation of spin-offs, including Kourtney and Khloé Take Miami (2009–2013) and Kourtney and Khloé Take The Hamptons (2014–2015). Following the ending of their previous show, she and her family began starring on Hulu's The Kardashians in 2022. From September 2009 to December 2016, Kardashian was married to basketball player Lamar Odom, whom she married one month after they first met. They starred in their own reality television series, Khloé & Lamar (2011–2012). In 2009, Kardashian participated in the second season of The Celebrity Apprentice, finishing 10th of 16 candidates after being fired by Donald Trump. In 2012, she co-hosted the second season of the American adaptation of The X Factor with actor Mario Lopez. In 2016, Kardashian hosted her own talk show, Kocktails with Khloé. She starred in and produced health and fitness docu-series Revenge Body with Khloé Kardashian from 2017 to 2019. In 2025, she began hosting her own weekly podcast called Khloe in Wonderland. Kardashian has been involved in the retail and fashion industries with her sisters Kourtney and Kim. They have launched several clothing collections and fragrances, and additionally released the book Kardashian Konfidential in 2010. The Dash boutique employees starred in their own short-lived reality television series, Dash Dolls (2015).
On September 20, 2024, the United States Court of Appeals for the Third Circuit overturned that decision, holding that federal law did not block plaintiffs' state law claims against Merck over Fosamax. As of June 30, 2024, about 3,115 lawsuits over Fosamax were still pending against Merck in both federal and state courts in the United States.
=== Progestogens === Progestins (progesterone-like drugs) such as megestrol acetate and medroxyprogesterone acetate have been used for the treatment of hormone-responsive, advanced breast cancer, endometrial cancer, and prostate cancer. Progestins are also used in the treatment of endometrial hyperplasia, a precursor to endometrial adenocarcinoma. The exact mechanism of action of these hormones is unclear, and may involve both direct effect on the tumor cells (suppression of estrogen receptor levels, alteration of hormone metabolism, direct cytotoxicity) and indirect endocrine effects (suppression of adrenal androgen production and plasma estrone sulfate formation).
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.